BI starts probe on Chinese man allegedly behind P1.8B drug shipment | Inquirer News

BI starts probe on Chinese man allegedly behind P1.8B drug shipment

By: - Reporter / @FMOrellanaINQ
/ 01:16 PM May 30, 2019

MANILA, Philippines — The Bureau of Immigration (BI) has started its probe on the allegation that a Chinese national who has frequented the Philippines is behind the P1.8 billion drug shipment that arrived in the country in March 22.

BI Spokesperson Dana Sandoval on Thursday said Immigration Commissioner Jaime Morente immediately ordered an investigation into the claim of Senator Panfilo Lacson about Zhijian Xu alias Jacky Co.

In a privilege speech on Wednesday, Lacson said Co is said to be included in the Interpol’s wachlist and has been frequenting the country despite being wanted by authorities in China.

Article continues after this advertisement

 

FEATURED STORIES

READ: Lacson names Chinese man behind P1.8-B drug shipment

However, according to Sandoval, there are no records at the BI have to prove Lacson’s allegations.

Article continues after this advertisement

“We learned about this yesterday afternoon, and Commissioner Morente immediately ordered a probe on this,” Sandoval said in a text message to INQUIRER.net

“Although initial verification showed that the names have no Interpol hit and no matching travel records, we are expanding the investigation with the help of other law enforcement and intelligence agencies,” she added.  (Editor: Mike U. Frialde)

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Jacky Co, Zhijian Xu

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.